Clinical experience with rosuvastatin in the management of hyperlipidemia and the reduction of cardiovascular risk

Expert Review of Cardiovascular Therapy

Volumn 9, Issue 11, 2011, Pages 1383-1390

  Nicholls, Stephen J ^a   Uno, Kiyoko ^a   Kataoka, Yu ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

atherosclerosis; cardiovascular disease; clinical trials; lipids; risk factors; rosuvastatin

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; ROSUVASTATIN;

ARTICLE; ATHEROMA; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DRUG ACTIVITY; DRUG HALF LIFE; DRUG TOLERABILITY; HUMAN; HYPERLIPIDEMIA; MYALGIA;

CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SULFONAMIDES;

EID: 80955130141     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.11.145     Document Type: Article

References (71)

1. Lloyd-Jones D, Adams R, Carnethon M et al. Heart disease and stroke statistics - 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 119, e21-e181 (2009).
2. Kannel WB, Dawber TR, Friedman GD, Glennon WE, McNamara PM. Risk factors in coronary heart disease. an evaluation of several serum lipids as predictors of coronary heart disease; the Framingham study. Ann. Intern. Med. 61, 888-899 (1964).
3. Anitschkow N and Chalatow S; translated by Pelias MZ. On experimental cholesterin steatosis and its significance in the origin of some pathological processes. Arterioscler. Thromb. Vasc. Biol. 3, 178-182 (1983).
4. Kannel WB, Dawber TR, Friedman GD et al. Risk factors in coronary heart disease. An evaluation of several serum lipids as predictors of coronary heart disease: the Framingham Study. Ann. Intern. Med. 61, 888-899 (1964).
5. Buja LM, Kita T, Goldstein JL et al. Cellular pathology of progressive atherosclerosis in the WHHL rabbit. An animal model of familial hypercholesterolemia. Arteriosclerosis 3, 87-101 (1983).
6. Kruth HS. Lipoprotein cholesterol and atherosclerosis. Curr. Mol. Med. 1, 633-653 (2001).
7. No authors listed. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).Lancet 344, 1383-1389 (1994).
8. Shepherd J. The West of Scotland Coronary Prevention Study: a trial of cholesterol reduction in Scottish men. Am. J. Cardiol. 76, 113C-117C (1995).
9. Sacks FM, Pfeffer MA, Moye LA et al.; Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med. 335, 1001-1009 (1996).
10. No authors listed. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N. Engl. J. Med. 339, 1349-1357 (1998).
11. Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279, 1615-1622 (1998).
12. Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366, 1267-1278 (2005).
13. Pedersen TR, Faergeman O, Kastelein JJ et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 294, 2437-2445 (2005).
14. LaRosa JC, Grundy SM, Waters DD et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. 352, 1425-1435 (2005).
15. Nissen SE, Nicholls SJ, Sipahi I et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 295, 1556-1565 (2006).
16. Baigent C, Blackwell L, Emberson J et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376, 1670-1681 (2010).
17. Hsia J, MacFadyen JG, Monyak J, Ridker PM. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin JACC 57 1666-1675 2011
18. Holdgate GA, Ward WH, McTaggart F. Molecular mechanism for inhibition of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase by rosuvastatin. Biochem. Soc. Trans. 31, 528-531 (2003).
19. Kapur NK. Rosuvastatin: a highly potent statin for the prevention and management of coronary artery disease. Expert Rev. Cardiovasc. Ther. 5, 161-175 (2007).
20. Istvan ES and Deisenhofer J. Structual mechanism for statin inhibition of HMG-CoA reductase. Science 292, 1160-1164 (2001).
21. Crestor® rosuvastatin product information. AstraZeneca Pharmaceuticals LP WIlmington, DE, USA (2010).
22. McTaggart F. Comparative pharmacology of rosuvastatin. Atheroscler. (Suppl. 4), 9-14 (2003).
23. Kostapanos MS, Milionis HJ, Elisaf MS. Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia. Am. J. Cardiovasc. Drugs 10, 11-28 (2010).
24. Nezasa K, Higaki K, Takeuchi M, Nakano M, Koike M. Uptake of rosuvastatin by isolated rat hepatocytes: comparison with pravastatin. Xenobiotica 33, 379-388 (2003).
25. Mach F, Sennouf D, Fontana P et al. Not all statins interfere with clopidogrel during antiplatelet therapy. Eur. J. Clin. Invest. 35, 476-481 (2005).
26. Riondino S, Petrini N, Donato L et al. Effects of rosuvastatin on platelet inhibition by clopidogrel in cardiovascular patients. J. Thromb. Thrombolysis 28, 151-155 (2009).
27. McKenney JM. Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks. Am. J. Cardiol. 96, 60E-66E (2005).
28. Schaefer JR, Schweer H, Ikewaki K et al. Metabolic basis of high density lipoproteins and apolipoprotein A-1 increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease. Atherosclerosis 144, 177-184 (1999).
29. Martin G, Duez H, Blanquart C et al. Statin-induced inhibition of the RHO-signaling pathway activates PPARalpha and induces HDL apoA-1. J. Clin. Invest. 107, 1423-1432 (2001).
30. Toth PP. High-density lipoprotein as a therapeutic target: clinical evidence and treatment strategies. Am. J. Cardiol. 96, 50K-58K (2005).
31. Ridker PM, Danielson E, Fonseca FA et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359, 2195-2207 (2008).
32. Ridker PM, Genest J, Boekholdt SM et al. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet 376, 333-339 (2010).
33. Jones PH, Davidson MH, Stein EA et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR.* Trial).Am. J. Cardiol. 92, 152-160 (2003).
34. Nicholls SJ, Brandrup-Wognsen G, Palmer M, Barter PJ. Meta-analysis of comparative efficacy of increasing dose of atorvastatin versus rosuvastatin versus simvastatin on lowering levels of atherogenic lipids (from VOYAGER).Am. J. Cardiol. 105, 69-76 (2010).
35. Barter PJ, Brandrup-Wognsen G, Palmer MK, Nicholls SJ. Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database. J. Lipid Res. 51, 1546-1553 (2010).
36. Kostapanos MS, Milionis HJ, Lagos KG, Rizos CB, Tselepis AD, Elisaf MS. Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia. Eur. J. Pharmacol. 590, 327-332 (2008).
37. Rosenson RS, Otvos JD, Hsia J. Effects of rosuvastatin and atorvastatin on LDL and HDL particle concentrations in patients with metabolic syndrome: a randomized, double-blind, controlled study. Diabetes Care 32, 1087-1091 (2009).
38. Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 96, 1432-1437 (1997).
39. Chambless LE, Heiss G, Folsom AR et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. Am. J. Epidemiol. 146, 483-494 (1997).
40. Hodis HN, Mack WJ, LaBree L et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann. Intern. Med. 128, 262-269 (1998).
41. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N. Engl. J. Med. 340, 14-22 (1999).
42. Amarenco P, Labreuche J, Lavallee P, Touboul PJ. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 35, 2902-2909 (2004).
43. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 357, 577-581 (2001).
44. Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 106, 2055-2060 (2002).
45. Crouse JR 3rd, Raichlen JS, Riley WA et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 297, 1344-1353 (2007).
46. Nissen SE, Tuzcu EM, Schoenhagen P et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291, 1071-1080 (2004).
47. Nicholls SJ, Tuzcu EM, Sipahi I et al. Effects of obesity on lipid-lowering, anti-inflammatory, and antiatherosclerotic benefits of atorvastatin or pravastatin in patients with coronary artery disease (from the REVERSAL Study).Am. J. Cardiol. 97, 1553-1557 (2006).
48. Ballantyne CM, Raichlen JS, Nicholls SJ et al. Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden. Circulation 117, 2458-2466 (2008).
49. Takayama T, Hiro T, Yamagishi M et al. Effect of rosuvastatin on coronary atheroma in stable coronary artery disease: multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS).Circ. J. 73, 2110-2117 (2009).
50. Nicholls SJ, Tuzcu EM, Sipahi I et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 297, 499-508 (2007).
51. Fayad ZA, Nahar T, Fallon JT et al. In vivo magnetic resonance evaluation of atherosclerotic plaques in the human thoracic aorta: a comparison with transesophageal echocardiography. Circulation 101, 2503-2509 (2000).
52. Corti R, Fayad ZA, Fuster V et al. Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high-resolution, noninvasive magnetic resonance imaging. Circulation 104, 249-252 (2001).
53. Corti R, Fuster V, Fayad ZA et al. Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years' follow-up by high-resolution noninvasive magnetic resonance imaging. Circulation 106, 2884-2887 (2002).
54. Underhill HR, Yuan C, Zhao XQ et al. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial. Am. Heart J. 155, 584.e1-e8 (2008).
55. Ridker PM, Danielson E, Fonseca FA et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 373, 1175-1182 (2009).
56. de Lorgeril M, Salen P, Abramson J et al. Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy. A critical reappraisal. Arch. Intern. Med. 170, 1032-1036 (2010).
57. Kaul S, Morrissey RP, Diamond GA. By Jove! What is a clinician to make of JUPITER? Arch. Intern. Med. 201, 170, 1073-1077 (2010).
58. Green LA. Cholesterol-lowering therapy for primary prevention, still much we don't know. Arch. Intern. Med. 170, 1007-1008 (2010).
59. Ridker PM, Glynn RJ. The JUPITER trial: responding to the critics. Am. J. Cardiol. 106, 1351-1356 (2010).
60. Glynn RJ, Danielson E, Fonseca FA et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N. Engl. J. Med. 360, 1851-1861 (2009).
61. GISSI-HF investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomized, double-blind, placebo-controlled trial. Lancet 372, 1231-1239 (2008).
62. Kjekshus J, Apetrei E, Barrios V et al. Rosuvastatin in older patients with systolic heart failure. N. Engl. J. Med. 357, 2248-2261 (2007).
63. McMurray JJ, Kjekshus J, Gullestad L et al. Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis. Circulation 120, 2188-2196 (2009).
64. Fellstrom BC, Jardine AG, Schmieder RE et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N. Engl. J. Med. 360, 1395-1407 (2009).
65. Wanner C, Krane V, Marz W et al. Atorvastatin in patients with Type 2 diabetes mellitus undergoing hemodialysis. N. Engl. J. Med. 353, 238-248 (2005).
66. Sharp Collaborative G. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am. Heart J. 160, 785-794.e10 (2010).
67. Shepherd J, Hunninghake DB, Stein EA et al. Safety of rosuvastatin. Am. J. Cardiol. 94, 882-888 (2004).
68. Sattar N, Preiss D, Murray HM et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375, 735-742 (2010).
69. Lee KK, Cipriano LE, Owens DK et al. Cost-effectiveness of using high-sensitivity C-reactive protein to identify intermediate - and low-cardiovascular-risk individuals for statin therapy. Circulation 122, 1478-1487 (2010).
70. Choudhry NK, Patrick AR, Glynn RJ. The cost-effectiveness of C-reactive protein testing and rosuvastatin treatment for patients with normal cholesterol levels. JACC 57, 784-791 (2011).
71. Goldstein LB, Bushnell CD, Adams RJ et al. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 42, 517-584 (2011).